SciELO - Scientific Electronic Library Online

vol.30 issue1Second lines in ovary cancer: is there a standard?Lymphomatoid granulomatosis: a little known entity author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Oncología (Barcelona)

Print version ISSN 0378-4835


COBO DOLS, M. et al. First line oral vinorelbine in elderly patients with advanced non-small-cell lung cancer. Oncología (Barc.) [online]. 2007, vol.30, n.1, pp.22-30. ISSN 0378-4835.

PURPOUSE: The activity of vinorelbine (VRL) as single agent in treatment-naïve inoperable non small cell cancer (NSCLC) patients (pts) has been assessed in several published studies. Oral and intravenous formulation have a linearity of VRL pharmacokinetics with both routes of administration. This is a study with oral VRL in first line advanced NSCLC in elderly pts. PATIENTS AND METHODS: A total of 12 chemonaive elderly pts > 70 years were recruited from October 2005 through to June 2006. Principal inclusion criteria included histologically confirmed advanced NSCLC, performance status < 2, measurable disease, appropriate bone marrow and organ function. The dosage schedule was 60 mg/m2 once a week for three weeks (first cycle), followed if not toxicity by 80 mg/m2 once a week, until disease progression or development of unacceptable toxicity. RESULTS: The mean age was 74 years (range: 71 to 79), all males, and all pts stage IV. Histology subtypes: adenocarcinoma in 5 pts, large cell carcinoma in 1 pts and squamous cell carcinoma in 6 pts. PS (ECOG) distribution was: 3 pts with PS 1, and 9 pts with PS 2. The median weekly VRL doses was 13 (range 3-23). Out of 11 pts receiving the second cycle, 7 patients went a dose escalation to 80 mg/m2. The other 4 pts remained at the 60 mg/m2 dose level. There were no complete responses (CR). Two (13%) of 12 patients achieved partial response (PR). There were 6 (50%) stable disease (SD) and 4 (34%) progressive disease (PD). Respect survival, the median follow-up was 4 months (range 1-9 months). Until date, the median survival time (MST) and median progression-free survival had not been reached; and survival and progression-free survival was 66% in both. Treatment with oral VRL in elderly patients was well tolerated, and there were no toxic deaths. No grade 4 toxicities were observed, and grade 3 toxicities were infrequent, exclusively neutropenia in 2 patients and asthenia in other 2 patients. Rest of toxicities were grade 1 or 2. CONCLUSIONS: Oral VRL appears to be a reasonable alternative intravenous VRL, both in terms of activity and tolerability in advanced, elderly NSCLC patients.

Keywords : Chemotherapy; Oral vinorelbine; Elderly; Non small cell lung cancer.

        · abstract in Spanish     · text in English     · English ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License